Vivesto completes recruitment in Paccal Vet study in cats and determines maximum tolerated dose
Vivesto completes recruitment in Paccal Vet study in cats and determines maximum tolerated dose
Solna, Sweden, July 1, 2026 – Vivesto AB, an oncology-focused development company, today announced that recruitment has been completed in the company’s ongoing Paccal Vet dose-finding study in cats with solid tumors. A total of 21 cats have been enrolled, with clear indications of anti-tumor effects observed, and the maximum tolerated dose (MTD) has been determined. Final results are expected in Q4 2026.
The primary objective of the study was to determine the MTD of Paccal Vet (paclitaxel micellar) in cats. In addition to establishing an appropriate dose for further development, the study includes exploratory assessments of Paccal Vet anti-tumor activity across diverse tumor types such as lymphoma and carcinoma. Cats with difficult-to-treat solid tumors, often after previous treatment options failure, have been included in the study.
“The completion of recruitment and MTD determination represent important progress for our Paccal Vet program in cats. The higher-than-expected MTD reflects the favorable tolerability observed during the study and provides us with a broader data set for assessing safety, dosing and early signs of anti-tumor activity. In parallel, initial signs of clinical responses on have been observed across several tumor types and dose levels, indicating that Paccal Vet could become a valuable treatment opportunity of cats who currently have no approved cancer therapies,” said Erik Kinnman, CEO of Vivesto.
The study was initially designed to include up to 12 cats in a 3+3 dose-escalation design. Recruitment was subsequently expanded as Paccal Vet was tolerated better than anticipated, allowing the study to continue into higher dose cohorts and include additional patients. In the study, cats are treated with up to four treatment cycles of Paccal Vet at three-week intervals across three clinical sites in the US. The study remains ongoing while enrolled cats complete treatment. The final results, expected in Q4 2026, are intended to support the next steps in the development of Paccal Vet for cats with cancer.